OnKure Therapeutics Inc. Ordinary Shares - Class A OKUR 深 滬
已收盤 07-18 16:00:00 美东时间
2.33
-0.050
-2.10%
華盛通- 最 高2.5901
- 今 開2.48
- 成交量 13.17万股
- 最 低 2.27
- 昨 收 2.38
- 總市值 3147.92万
- 52周最高 19.9992
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 1.70
- 委 比 -82.91%
- 總股本 1351.04万
- 歷史最高 19.9992
- 量 比 1.35
- 振 幅 13.45%
- 歷史最低 1.70
- 每 手 1
- 風險率 5.71%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多OnKure Therapeutics Updates on PI3Kα Inhibitor Progress
OnKure Therapeutics ( ($OKUR) ) has shared an announcement. On June 26, 2025, O...
06-27 04:49
美股大行评级 | Evercore ISI集团：维持苹果"跑赢大市"评级，目标价从260美元升至275美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1109037475621081088.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• HC Wainwright & Co.：维持Black Diamond Therapeutic(BDTX)"买入"评级，目标价从11美元升至12美元</p> <p>• 康托·菲茨杰拉德：维持Disc Medicin
03-19 09:24
Onkure Therapeutics Faces Stiff Competition in the Pharmaceutical Sector: Challenges in Commercializing PI3Ka Therapies
Onkure Therapeutics, Inc. (OKUR) has disclosed a new risk, in the Competition c...
03-12 14:00
美股大行评级 | 美银证券：维持雅培"买入"评级，目标价从133美元升至150美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1106501041932570625.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Roth MKM：维持CervoMed Inc.(CRVO)"买入"评级，目标价从7美元升至15美元</p> <p>• Oppenheimer：维持Trevi Therapeutics(TRVI)"跑赢大市"评级，目标价从
03-12 11:01
OnKure Therapeutics GAAP EPS of -$1.37
OnKure Therapeutics press release (NASDAQ:OKUR): Q4 GAAP EPS of -$1.37. Cash and cash equivalents were approximately $110.8 million as of December 31, 2024. More on OnKure Therapeutics Historical ea...
03-11 04:38
OnKure Therapeutics Q4 2024 GAAP EPS $(1.37) Misses $(0.74) Estimate
OnKure Therapeutics (NASDAQ:OKUR) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(0.74) by 85.14 percent.
03-11 04:13
JonesTrading Reaffirms Their Buy Rating on OnKure Therapeutics (OKUR)
In a report released today, Soumit Roy from JonesTrading reiterated a Buy ratin...
02-06 05:15
美股机会日报丨美联储新年首秀按兵不动！特朗普炮轰鲍威尔；芯片股盘前走高
美联储新年首秀按兵不动！特朗普炮轰鲍威尔 ；DeepSeek引发美科技股抛售潮后，高盛：远没到进入熊市的节奏；芯片股盘前反弹，博通涨超5%，迈威尔科技涨超4%>>
01-30 21:40
美股机会日报丨重磅！今夜美联储议息决议来袭；阿斯麦盘前涨超5%
重磅！今夜美联储议息决议来袭；“美联储传声筒”：关税是美联储政策的关键变数；阿斯麦Q4营收、利润超预期，盘前涨超5%>>
01-29 21:23
美股大行评级 | 英伟达获机构上调目标价至220美元！大摩予AKRO“超配”评级
摩根士丹利：维持Akero Therapeutics(AKRO)"超配"评级，目标价从46美元升至96美元
01-29 16:47
